<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567863</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A00276-49</org_study_id>
    <nct_id>NCT03567863</nct_id>
  </id_info>
  <brief_title>Study Comparing Pancreatic EUS-FNB With the 20-gauge Procore® and the 22-gauge Acquire® Needles</brief_title>
  <acronym>HISTOPAN</acronym>
  <official_title>Multicentric Randomized Study Comparing the Histological and Molecular Material Quality Obtained by EUS-FNB of Pancreatic Mass With Two &quot;Biopsic&quot; Needles: the 20-gauge Procore® (Cook) and the 22-gauge Acquire® (Boston Scientific)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Société Française d'Endoscopie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Société Française d'Endoscopie Digestive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter randomized prospective study

      Criteria for inclusion:

      Patients admitted for EUS-FNB of a pancreatic mass

      Goals of the study:

      To compare the results of blinded punctures for suspicion of pancreatic tumor performed under
      endoscopic ultrasound in our center (Digestive Endoscopy Unit of the Digestive Pole Paris
      Bercy, PDPB), in terms of diagnosis and quality of histopathological material obtained with
      the help of 20G Procore, Cook and 22G Acquire needles, Boston Scientific.

      Main criterion:

      - Biopsy core length of target tissue obtained by needle pass

      Number of patients:

      60 patients

      Duration of the study:

      1 year
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type of study:

      Multicenter randomized prospective study

      Criteria for inclusion:

      Patients admitted for ENDOSCOPIC ULTRASOUND FINE NEEDLE BIOPSY (EUS-FNB) of a pancreatic mass

      Exclusion criteria:

      Patients with an extra-pancreatic mass puncture Echendoscopic puncture contraindication or
      vascular interposition

      Goals of the study:

      To compare the results of blinded punctures for suspicion of pancreatic tumor performed under
      endoscopic ultrasound in our center (Digestive Endoscopy Unit of the Digestive Pole Paris
      Bercy, PDPB), in terms of diagnosis and quality of histopathological material obtained with
      the help of 20G Procore, Cook and 22G Acquire needles, Boston Scientific.

      Evaluation criteria :

      Main criterion:

      - Biopsy core length of target tissue obtained by needle pass

      Secondary criteria

        -  Presence of a core biopsy specimen

        -  Sensitivity of EUS-FNB for the diagnosis of adenocarcinoma of the pancreas

        -  False negative rate, Negative predictive value for the diagnosis of pancreatic
           adenocarcinoma

        -  Computer Aided Morphometric Evaluation of the Tumor + Stroma Surface on All core biopsy
           specimens

        -  Success rate of isolation of tumor cells and determination of transcriptomic signatures
           of pancreatic adenocarcinoma subtypes

        -  Immediate complications of puncture

        -  Variation in the quality of the puncture following the trans-duodenal or trans-gastric
           access route

        -  Technical failure rate of puncture

        -  Optional: inter and intra-observer evaluation of the anatomopathological criteria used
           (presence of a biopsy core, length of target tissue core per needle passage)

      Number of patients:

      60 patients

      Duration of the study:

      1 year
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 24, 2018</start_date>
  <completion_date type="Actual">September 29, 2019</completion_date>
  <primary_completion_date type="Actual">September 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>the order of use of the 2 needles is not communicated to the cytologist</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative length of tissue core biopsies per needle pass</measure>
    <time_frame>in the 7 days after procedure</time_frame>
    <description>cumulative length of tissue core biopsies per needle pass in mm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of core biopsy specimen</measure>
    <time_frame>in the 7 days after procedure</time_frame>
    <description>Presence of core biopsy specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>in the 7 days or 6 months</time_frame>
    <description>EUS-FNB Sensitivity for the diagnosis of adenocarcinoma of the pancreas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>in the 7 days or 6 months</time_frame>
    <description>EUS-FNB Specificity for the diagnosis of adenocarcinoma of the pancreas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Predictive Value</measure>
    <time_frame>in the 7 days or 6 months</time_frame>
    <description>EUS-FNB Positive predictive value for the diagnosis of adenocarcinoma of the pancreas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Predictive Value</measure>
    <time_frame>in the 7 days or 6 months</time_frame>
    <description>EUS-FNB Negative Predictive Value for the diagnosis of adenocarcinoma of the pancreas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Computer Aided Morphometric Evaluation of the Tumor + Stroma Surface</measure>
    <time_frame>6 months</time_frame>
    <description>Computer Aided Morphometric Evaluation of the Tumor + Stroma Surface on All Core biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of isolation of tumor cells</measure>
    <time_frame>6 months</time_frame>
    <description>Success rate of isolation of tumor cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>7 days</time_frame>
    <description>Puncture Morbidity (acute pancreatitis, haemorrhage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>during procedure</time_frame>
    <description>Technical failure rate of puncture because of a impossibility to access to pancreatic mass with the needle (due to the needle stiffness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inter evaluation of the anatomopathological criteria used (presence of a biopsy core, length of target tissue core per needle pass)</measure>
    <time_frame>7 days</time_frame>
    <description>inter evaluation of the anatomopathological criteria used (presence of a biopsy core, length of target tissue core per needle pass)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of transcriptomic signatures of pancreatic adenocarcinoma subtypes</measure>
    <time_frame>6 months</time_frame>
    <description>determination of transcriptomic signatures of pancreatic adenocarcinoma subtypes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra-observer evaluation of the anatomopathological criteria used</measure>
    <time_frame>7 days</time_frame>
    <description>intra-observer evaluation of the anatomopathological criteria used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pancreas Cancer</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®</intervention_name>
    <description>The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®</intervention_name>
    <description>The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient admitted to one of the investigative centers for endoscopic pancreatic
             puncture during the period from April 1, 2018 to April 1, 2019

          -  Patient whose age is greater than or equal to 18 years and less than 90 years

          -  Patient ASA 1, ASA 2, ASA 3 (ASA: American Society of Anaesthesiologists
             Classification)

          -  Lack of participation in another clinical study

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients punctured with an extra-pancreatic mass

          -  Patient under the age of 18 or over 90

          -  Patient ASA 4, ASA 5

          -  Pregnant woman

          -  Patient with coagulation abnormalities preventing puncture: TP &lt;50%, Platelets &lt;50000
             / mm3, effective anticoagulation in progress, clopidogrel in progress

          -  Vascular or ductal or surgical fixation (Billroth II, Roux in Y) preventing endoscopic
             access to the lesion to be punctured

          -  Patient unable to personally consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Karsenti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Société Française d'Endoscopie Digestive</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Karsenti</name>
      <address>
        <city>Charenton-le-Pont</city>
        <state>Ile De France</state>
        <zip>94220</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>September 29, 2019</last_update_submitted>
  <last_update_submitted_qc>September 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Société Française d'Endoscopie Digestive</investigator_affiliation>
    <investigator_full_name>KARSENTI</investigator_full_name>
    <investigator_title>MD, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

